Endevica Bio's Pioneering Phase 2 Clinical Trial
Endevica Bio, a privately held firm focused on innovative peptide drug development, has marked a significant milestone by dosing the first patient in a Phase 2 trial for TCMCB07 (B07), a promising treatment aiming to combat weight loss in cancer patients undergoing chemotherapy. This pivotal trial seeks to address a crucial need for patients battling stage 4 metastatic colorectal cancer.
Trial Overview and Objectives
The Phase 2 clinical trial is conducted in collaboration with WuXi Clinical and encompasses a network of 20 sites, engaging 100 patients diagnosed with stage 4 metastatic colorectal cancer. These patients will receive doses of B07 concurrently with their chemotherapy treatment. The principal goal of this trial involves preventing significant weight loss that often leads to cachexia—a serious and potentially life-threatening condition characterized by extreme weight loss and muscle wasting.
Commitment to Innovation in Cancer Care
Russell Potterfield, Chief Executive Officer and Executive Chair of Endevica Bio, expressed the company's commitment to advancing treatments for cachexia, stating, "Every trial moves us toward offering effective solutions for management of this increasingly prevalent disorder, impacting many lives. Our dedication remains steadfast in pursuing breakthroughs for patients in need.”
Importance of TCMCB07
Dr. Daniel Marks, Chief Medical and Scientific Officer at Endevica Bio, shared his enthusiasm regarding the trial. He emphasized its significance in light of the lack of FDA-approved therapies targeting cancer cachexia. “This trial represents a major progression toward providing vital treatment for a significant clinical gap, and we eagerly anticipate the outcomes,” he said. The research showcases the innovative approach Endevica Bio adopts in developing solutions for challenging health issues.
Results and Findings of Preliminary Trials
In the previous year, Endevica Bio successfully completed its Phase 1 clinical trial, where initial results indicated strong safety and effectiveness for B07. Notably, findings published in a prominent clinical journal indicated that B07 notably improved appetite and helped maintain both lean mass and fat mass in rodent models subjected to chemotherapy. Moreover, this evidence points to B07's potential in reducing the risk of treatment-related anorexia and weight reduction for a vast number of cancer patients globally.
The Science Behind TCMCB07
TCMCB07 is an experimental peptide designed to act as a melanocortin?3/4 antagonist. Its unique formulation allows it to penetrate the blood-brain barrier, targeting receptors that were previously unreachable. This targeting capability influences the body's responses to chronic illnesses and can potentially modulate behaviors and metabolic processes related to cachexia. Preclinical trials have shown promising results, demonstrating preservation of lean muscle mass during drug administration in various chronic disease contexts.
Endevica Bio's Vision
Endevica Bio is dedicated to creating first-in-class peptide therapeutics. The company’s proprietary technology, safeguarded by an extensive array of patents, offers a foundation for engineering peptides that enhance the targeting of vital biological systems beyond the challenges posed by the blood-brain barrier. This tailored approach marks a transformative step in the fight against cachexia and similar conditions.
Contact Information for Media Inquiries
For further information about Endevica Bio and its groundbreaking research, please reach out to Dan Marks, who is available for media and public relations inquiries.
Frequently Asked Questions
What is the primary focus of Endevica Bio's Phase 2 trial?
The trial focuses on evaluating the effectiveness of TCMCB07 to prevent weight loss in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.
What condition is TCMCB07 aiming to address?
TCMCB07 aims to treat cachexia, a serious condition that causes significant weight loss and muscle wasting in cancer patients.
How many patients are involved in the trial?
The trial includes 100 patients diagnosed with advanced colorectal cancer.
What has previously been demonstrated in Phase 1 trials?
Phase 1 trials showed promising safety and efficacy results for B07, indicating its potential to benefit cancer patients.
Who can be contacted for media inquiries about the trial?
Dan Marks is the primary contact for any media inquiries related to Endevica Bio and its clinical research endeavors.
